|Classification and external resources|
This condition is caused by the rocking motion of the craft. Most people tend to concentrate on the inner surroundings,[clarification needed] or close the eyes and try to sleep. This will cease the worst effect of the disturbance.
The real cause is in the brain, which receives conflicting signals: while the eyes show a world that is still, our body, and in particular the equilibrium sensors located in our ears, send signals of a moving environment. This discordance causes the mind to send to the whole body a general alarm signal, in order to stop all activities,[clarification needed] in particular the most complex of all: the digestion process.
Benson suggests that motion sickness should be broadly addressed through reduction of stimuli and improved ship hull design. For individuals, desensitization through gradually increasing stimuli is advocated. Cognitive-behavioral training may also lessen responses to provocative motions.
The same syndrome: GHTH be experienced hiking at high altitudes.
Over-the-counter medications such as Cinnarizine/Stugeron and prescription medications such as dimenhydrinate, scopolamine and promethazine (as transdermal patches and tablets) are readily available. As these medications often have side effects, anyone involved in high-risk activities while at sea (such as SCUBA divers) must evaluate the risks versus the benefits. Promethazine is especially known to cause drowsiness, which is often counteracted by ephedrine in a combination known as "the Coast Guard cocktail."
- Balance disorder
- Broken escalator phenomenon
- Ideomotor phenomenon
- Illusions of self-motion
- Mal de debarquement
- Space sickness
- Spatial disorientation
- Benson, Alan J. (2002). "Motion Sickness". In Kent B. Pandoff and Robert E. Burr. Medical Aspects of Harsh Environments 2. Washington, D.C.: Borden Institute. pp. 1048–1083. ISBN 978-0-16-051184-4. Retrieved 4 Dec 2012.
- Shri Kamal Sharma (1 January 1992). Resource Utilization and Development: A Perspective Study of Madhya Pradesh, India. Northern Book Centre. pp. 1078–. ISBN 978-81-7211-032-1. Retrieved 30 June 2013.
- Robert William Baloh; Vincente Honrubia (2001). Clinical Neurophysiology of the Vestibular System. Oxford University Press. pp. 127–. ISBN 978-0-19-513982-2. Retrieved 30 June 2013.
- Weinstein SE, Stern RM (October 1997). "Comparison of marezine and dramamine in preventing symptoms of motion sickness". Aviation, Space, and Environmental Medicine 68 (10): 890–4. PMID 9327113.
- Spinks AB, Wasiak J, Villanueva EV, Bernath V (July 2007). "Scopolamine (hyoscine) for preventing and treating motion sickness". In Wasiak, Jason. Cochrane Database of Systematic Reviews 18 (3): CD002851. doi:10.1002/14651858.CD002851.pub3. PMID 17636710.
- "Phenergan information". Drugs.com. Retrieved 2009-07-10.
- Schwartz, Henry JC and Curley, Michael D (1986). "Transdermal Scopolamine in the Hyperbaric Environment". United States Navy Experimental Diving Unit Technical Report. Retrieved 2008-05-09.
- Bitterman N, Eilender E, Melamed Y (May 1991). "Hyperbaric oxygen and scopolamine". Undersea Biomedical Research 18 (3): 167–74. PMID 1853467. Retrieved 2008-05-09.
- Williams TH, Wilkinson AR, Davis FM, Frampton CM (March 1988). "Effects of transcutaneous scopolamine and depth on diver performance". Undersea Biomedical Research 15 (2): 89–98. PMID 3363755. Retrieved 2008-05-09.
- Arieli R, Shupak A, Shachal B, Shenedrey A, Ertracht O, Rashkovan G (1999). "Effect of the anti-motion-sickness medication cinnarizine on central nervous system oxygen toxicity". Undersea and Hyperbaric Medicine 26 (2): 105–9. PMID 10372430. Retrieved 2008-05-09.
- East Carolina University Department of Diving & Water Safety. "Seasickness: Information and Treatment".